

**THE DEVELOPMENT OF LIPOSOME  
ENCAPSULATED CALCIUM PHOSPHATES  
FOR BONE REGENERATION**

A thesis submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy

by

**KANTHI LEWIS**

B.Sc. Applied Chemistry (Hons)

2010



### **CERTIFICATE OF AUTHORSHIP/ORIGINALITY**

I, Kanthi Lewis, certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of requirements for a degree except as fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

Production Note:

Signature removed prior to publication.

Signature

## Acknowledgements

First and foremost I would like to thank Dad. You always taught me to see through everything I commit to, no matter how tough it gets. Thanks for all the encouragement, love, support and belief you always had in me. Knowing how proud you have always been, even now that you are not here to remind me, always gives me strength to persevere.

Without you this would not have been possible, and this thesis is dedicated to your memory.

I would like to thank my wonderful supervisors Prof Besim Ben-Nissan, Dr Stella Valenzuela and Dr Louise Evans who have been incredibly supportive, and given me guidance these last 4 years. Always generous with your time and energy, I have learnt more than I ever thought possible, and I could not have asked for better supervisors.

Prof Racquel LeGeros, taking me on and mentoring me through my year at NYU, the experience was invaluable, and it has been an absolute privilege to learn from you.

I would also like to thank all the UTS staff particularly Mr Mark Berkhahn, Mr Ric Wurher, and Dr Ronald Shimmon, for help with the X-ray, Imaging, Mapping, Organic Synthesis and NMR, and Ms Linda Foley, Ms Era Koirala, all your help with ordering and generally make life as a PhD student much easier.

Dr Kristina Warton, Mr Nicholas Archer and Ms Stephanie Dowdell for all the assistance with the PCR, for always being there to help when I got to my wits end.

Dr Murray Killingsworth from Electron Microscopy Laboratory, South Western Area Pathology Service, for processing, sectioning and TEM imaging the liposomes.

Dr Dindo Mijares, I appreciate all your time and effort in the lab and helping me adjust.

Dr Yuexun Liu for your help with the PCR data analysis

Dr Catherine Kealley, you always listened and understood. Always a few steps ahead, you were a great source of advice, so often my shoulder to lean on, and a wonderful friend.

My fellow PhD students, Dr Julia Ting, and Dr Dakrong Pissuwan, who made the lab a much brighter place, and always willing to be a helping hand.

I would like to thank all my family and friends for all your love and support

## ABSTRACT

Osteoporosis, a degenerative bone disorder, is one of the leading causes of morbidity in the elderly. Proper nutrition plays a role in the prevention and treatment of osteoporosis. Intake of calcium and Vitamin D are some of the most important nutritional factors, and supplementation remains the gold standard and first line of treatment for low bone mineral density and osteoporosis. Supplementation can prevent bone loss and reduce fracture risk.

This work set about to produce, characterise and encapsulate for direct delivery to the bone various micro and nano sized calcium based mineral compounds which may be beneficial to bone health, using the precipitation method and biomimetic processes.

Calcium phosphate mineral was produced and characterised, including hydroxyapatite (Hap), dicalcium phosphate dihydrate (DCPD), as well as multiphase and substituted calcium phosphates using biomimetic process. Standard simulated body Fluid (SBF) solution was modified, creating a high carbonate solution which better mimics the bone environment, and produces precipitates more similar to bone than traditional low carbonate SBF, as confirmed using Fourier Transform Infrared Spectroscopy (FTIR) and X-Ray Diffraction (XRD).

The use of liposomes as a delivery vesicle for the calcium mineral was evaluated using FTIR, XRD, Electron Dispersive Spectroscopy, Mass Spectrometry Transmission and Scanning Electron Microscopy, and X-Ray Mapping. The calcium mineral from aqueous solutions and prepared HAp and DCPD was incorporated into the liposome.

Functional groups were synthesised based on a published structure used to target the bone marrow macrophage, and incorporation into liposomes was confirmed using Nuclear Magnetic Resonance Spectroscopy and FTIR. Preliminary cell culture studies showed no direct effect on osteoblast like Mg63 or Saos-2 cells or osteoclast resorption, measured by bone collagen release.

Macrophage response was explored using U937 cell line. Expression of TNF- $\alpha$  and IL-1, markers of inflammation, increased with liposome treatments compared to the negative control but decreased compared the positive control. The Mg63 cells given U937 supernatants showed liposomes increased OPG production, but this was regardless of mineralisation.

The calcium based mineral compounds were produced, characterised, successfully encapsulated using liposomes and functionalised to improve uptake at the bone site. This shows the potential to deliver calcium to the bone, however further work to inhibit inflammation and increase the calcium dose to elicit greater cell response is required before this approach can be developed as a treatment option.

# Table of Contents

<b>Certificate of Authorship</b>	<b>i</b>
<b>Acknowledgements</b>	<b>ii</b>
<b>Abstract</b>	<b>iii</b>
<b>List of Abbreviations</b>	<b>vii</b>
<b>List of Figures</b>	<b>x</b>
<b>List of Equations</b>	<b>xvii</b>
<b>List of Tables</b>	<b>xviii</b>
<b>Chapter 1 Introduction</b>	
1.1 Significance	2
1.2 Aims	2
1.3 Summary of thesis outline	3
1.4 Outline of the thesis	4
<b>Chapter 2 Literature review</b>	
2.1 Bone	7
2.2 Bone Classification	7
Bone Microstructure	8
2.3 Bone Composition	9
Organic Matrix	10
Inorganic Phase	11
Bone Cells	13
Lipids	14
Interstitial fluid	14
2.4 Bone Decomposition	15
2.5 Osteoporosis pathophysiology	15
Current treatments for Osteoporosis	18
Model Systems for studying Osteoporosis pathogenesis	21
2.6 The importance of Lipids in bone health	25
2.7 Liposomes	27
2.4 Bone Cell Activity	32
Markers of bone activity	34
Macrophage bone activity	36
2.8 References	44
<b>Chapter 3 Mineral Production and Characterisation</b>	
3.1 Introduction	51
3.2 Mineral Production	54
Production of Simulated body fluid and Precipitation	54
Production of mineral from alternate calcified solutions	60
Production of Calcium phosphate mineral	62



3.3 Mineral Characterisation Methods	65
Fourier transform Infrared Spectroscopy	65
X-Ray Diffraction	66
3.4 Mineral Characterisation	68
3.5 Summary of Chapter findings	77
3.6 References	78
<b>Chapter 4 Liposome and functional group production and Characterisation</b>	
4.1 Introduction	80
4.2 Preparation of Liposomes	82
4.3 Methods of Characterisation	84
Transmission Electron Microscopy	84
Nuclear Magnetic Resonance Spectroscopy	86
4.4 Characterisation of Liposomes	88
4.5 Functional Group production method	94
4.6 Functional group characterisation	95
4.7 Production of functionalised liposomes	100
4.8 Characterisation of functionalised liposomes	102
4.9 Summary of chapter findings	103
4.10 References	104
<b>Chapter 5 Liposome Mineral incorporation</b>	
5.1 Introduction	106
5.2 Methods of Characterisation	109
Scanning Electron Microscopy	110
Xray Mapping	111
Inductively coupled plasma- Mass Spectrometry	112
5.3 Characterisation of Mineralised Liposomes	113
5.4 Characterisation of Sample Set 1	118
5.5 Characterisation of Sample Set 2	124
5.6 Characterisation of Sample Set 3	129
5.7 Summary of Chapter findings	139
5.8 References	140
<b>Chapter 6 Osteoblast and osteoclast response</b>	
6.1 Introduction	142
6.2 Primary Cell Culture	144
Bone Collection	144
Cell culture method for osteoblast isolation	145
6.3 Cell Lines	147
6.4 Methods for determining Cytotoxicity and Proliferation	150
Cytotoxicity and liposome dose determination	150
Proliferation assay method	152
6.5 Methods of cell differentiation determination	153
Alkaline Phosphatase Activity	153

Osteocalcin Production	154
Osteoprotegerin Production	155
6.6 Cytotoxicity and proliferation assay results	157
6.7 Results of osteoblast differentiation assays	162
6.8 Osteoclast culture and differentiation methods	166
Trap Assay	167
Collagen release	169
6.9 Results of osteoblast differentiation assays	171
6.10 Discussion of cell culture findings	173
6.11 Summary of Chapter findings	176
6.12 References	177
<b>Chapter 7</b> <b>Macrophage cell culture</b>	
7.1 Introduction	179
7.2 U937 cell culture methods	180
Proliferation	181
Differentiation	184
Background to PCR	184
PCR method	186
PCR results	194
7.3 Mg63 response to U937 cytokines	196
Proliferation and differentiation	196
Alkaline Phosphatase activity	197
Osteoprotegerin production	198
7.4 Discussion of results	199
7.5 Summary of chapter findings	202
7.6 References	203
<b>Chapter 8</b> <b>Conclusions and Further Work</b>	
8.1 Conclusions and further work	206
8.2 References	217
<b>Appendix A</b> <b>X-ray Diffraction reference patterns</b>	219
<b>Appendix B</b> <b>Statistical analysis for cell culture</b>	221

## List of Abbreviations

Alkaline phosphatase (ALP)  
Back scattered electron (BSE)  
Bone mineral density (BMD)  
Bovine serum albumin (BSA )  
Calcium acetate (Ca(Ac)<sub>2</sub>)  
Colony stimulating factor-1 (CSF-1)  
Dicalcium phosphate dihydrate (DCPD)  
Environmental Scanning Electron Microscope (ESEM)  
Enzyme linked immunosorbent assay (ELISA)  
Ethylene diaminetetra acetic acid (EDTA)  
Extracellular matrix (ECM)  
Foetal Bovine Serum (FBS)  
Fourier Transform Infrared Spectroscopy (FTIR)  
Gaseous secondary electron (GSE)  
Hormone replacement therapy (HRT)  
Horseradish peroxidase (HRP).  
Hydroxyapatite (Hap)  
Inductively coupled plasma (ICP).  
Institutional Animal Care and Use Committee (IUCAC)  
Insulin like growth factor 1 (IGF-I)  
Interferon- $\gamma$  (IFN  $\gamma$ ),  
Interleukin (IL),  
Latent TGF- $\beta$  binding protein (LTBP)-1  
Macrophage colony stimulating factor (MCSF)  
Macrophage inflammatory protein-1 alpha (MIP-1a)



Mass spectrometry (MS)

Monocyte chemoattractant protein-1 (MCP-1)

Monoclonal antibodies (Mabs)

Propidium Iodide (PI)

Raloxifene (RAL)

Receptor Activator for Nuclear Factor  $\kappa$  B Ligand (RANK-L)

Repetitions per minute (RPM)

New York University (NYU)

Nuclear factor- $\kappa$ B ligand /RANK ligand (RANKL)

Nuclear magnetic Resonance Spectroscopy (NMR).

Osteoprotegerin (OPG)

Ovariectomized (OVX)

Parathyroid hormone (PTH),

Phosphate Buffered Saline (PBS)

Phosphatidylcholine (PC)

Polymerase Chain Reaction (PCR)

p-nitrophenol (pNp)

p-nitrophenol phosphate (p-Npp)

Reactive oxygen species (ROS)

Ribonucleic Acid (RNA)

Scanning electron microscope (SEM)

Simulated body Fluid (SBF)

Small integrin-binding ligand N-linked glycoprotein (SIBLING) family

Tartrate-resistant acid phosphatase type 5b (TRAcP-5b)

Tetramethylbenzidine (TMB)

T helper 1 ( $T_H1$ )

Transmission electron microscopy (TEM).

Transforming growth factor (TGF)- $\beta$

Tumour-necrosis factor (TNF)

United States Department of Agriculture (USDA).

University of Technology, Sydney (UTS)

Width of Field (WOF)

X-ray Diffraction (XRD)

X-Ray Mapping (XRM)

7-dehydrocholesterol (7- DHC)

1,25-dihydroxyvitaminD<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>).

1,2 distearoyl-sn-glycero-3-phospho-ethanolamine-N-[monomethoxy poly(ethylene glycol)  
5000 (PEG-DSPE)

1,5 Dipalmitoyl-L-glutamate-N-succinic acid (LGSA)

## List of Figures

### Chapter 1

No Figures in Chapter 1

### Chapter 2

Figure 2.1 Examples of the four bone types shown in the human skeleton.

Figure 2.1 Microstructure of bone modified

Figure 2.2 Unit cell structure of HAp

Figure 2.4 Cell activity in bone, showing osteoblasts in bone formation and osteoclasts resorbing bone

Figure 2.5 An imbalance between bone formation and resorption leads to trabecular thinning (left) and eventual loss of trabecular connectivity (right)

Figure 2.6 Cationic lipids activating the cellular activity

Figure 2.7 Structure of SA

Figure 2.8 A schematic representation of different liposome types

Figure 2.9 Liposomes with the four types of functionalisation.

Figure 2.10 Schematic of active osteoclast and osteoclasts

Figure 2.11 Bone resorption and formation

Figure 2.12 Osteoclast differentiation pathway

Figure 2.13 Cytokines affecting the osteoclast.

Figure 2.14 Monocyte differentiation

Figure 2.15 Cationic lipid effect on cell activity

Figure 2.16 Activated T cells induce osteoclast genesis

## Chapter 3

Figure 3.1 Outline of mineral production and characterisation.

Figure 3.2 Synthesis setup for the preparation of hydroxyapatite

Figure 3.3 Diffraction from crystal planes.

Figure 3.4 FTIR spectrum of mineral produced from a) low carbonate SBF b) high carbonate SBF c) low carbonate SBF with Fluoride

Figure 3.5 FTIR spectrum of a) Hydroxyapatite b) Dicalcium phosphate dehydrate c) calcium carbonate

Figure 3.6 X-ray diffraction pattern of mineral obtained from a) low carbonate SBF solution with JCPDS sodium chloride reference pattern b) high carbonate SBF solution with JCPDS sodium chloride reference pattern c) low carbonate SBF solution containing fluoride with JCPDS sodium chloride reference pattern

Figure 3.7 X-ray diffraction pattern hydroxyapatite with JCPDS hydroxyapatite reference

Figure 3.8 X-ray diffraction pattern of Hydroxyapatite with JCPDS calcium hydrogen phosphate hydrate reference pattern

Figure 3.9 X-ray diffraction pattern of dicalcium phosphate dihydrate with JCPDS dicalcium phosphate dihydrate (Brushite) reference pattern

Figure 3.10 X-ray diffraction pattern of calcium carbonate with JCPDS calcium carbonate reference pattern

## Chapter 4

Figure 4.1 Outline of production and characterisation of liposomes

Figure 4.2 Structure of Phosphatidylcholine

Figure 4.3 Multilamellar liposomes with hydrophobic tails grouping together, and polar heads in contact with aqueous solution.

Figure 4.4 TEM image of unilamellar liposomes with mineralised portions indicated by green arrows.

Figure 4.5 TEM image of Unilamellar liposomes with some multilamellar samples beginning to form and shown with red arrows.

Figure 4.6 TEM image of a mix of multilamellar and unilamellar liposomes produced in a calcifying buffer unilamellar liposomes shown by green arrows in these images and multilamellar liposomes in red.

Figure 4.7 TEM image of a mix of multilamellar and unilamellar liposomes produced in a calcifying buffer

Figure 4.8 TEM image of a unilamellar liposome produced in a calcifying buffer

Figure 4.9 TEM image of multilamellar liposomes in a calcifying buffer

Figure 4.10 TEM image of multilamellar liposomes in a calcifying buffer.

Figure 4.11 The structure of compound 1. 1-glutamic acid, *N*-(3-carboxy-1-oxopropyl)-, 1,5-dihexadecyl ester

Figure 4.12 The structure of L-glutamine, the four Hydrogen environments that appear in the NMR spectrum are numbered

Figure 4.13 The structure of hexadecyl alcohol, the four Hydrogen environments that appear in the NMR spectrum are numbered

Figure 4.14 H-NMR spectrum of starting materials, a) L-glutamine b) hexadecyl alcohol

Figure 4.15 H-NMR spectrum of compound 1- a) before purification b) after purification

Figure 4.16 H-NMR spectrum of Compound 2- 1,5 dipalmitoyl-L-glutamate-N-succinic acid

Figure 4.17 FTIR spectrum of a) compound 1 after purification b) compound 2- 1,5 Dipalmitoyl-L-glutamate-N-succinic acid

Figure 4.18 H-NMR spectrum of liposome a) without PEG b) with spontaneously incorporated PEG



## Chapter 5

Figure 5.1 Summary of Liposome Characterisation

Figure 5.2 TEM image of a multilamellar liposomes, produced in SBF

Figure 5.3 Image of liposomes taken using ESEM in SE mode showing multilamellar liposomes.

Figure 5.4 EDS spectra of the liposomes on the TEM grid

Figure 5.5 Backscatter images of liposomes in SBF solution.

Figure 5.6 EDS of liposomes plus SBF.

Figure 5.7 Pseudo colour images sample set 1 a) liposomes in PBS Control b) Liposomes in PBS plus HAp c) Liposomes in PBS plus DCPD

Figure 5.8 EDS sample set 1 a) liposomes in PBS Control b) Liposomes in PBS plus HAp c) Liposomes in PBS plus DCPD.

Figure 5.9 scatter diagrams sample set 1 a) liposomes in PBS Control b) Liposomes in PBS plus HA c) Liposomes in PBS plus DCPD, showing the correlation between calcium and phosphate

Figure 5.10 Elemental mapping diagram liposomes in PBS Control

Figure 5.11 Elemental mapping diagram Liposomes in PBS plus HA

Figure 5.12 Elemental mapping diagram Liposomes in PBS plus DCPD

Figure 5.13 Representation of calcium ions binding to the phosphate layer of the liposome

Figure 5.14 Pseudo colour images of sample set 1 a) liposomes in low CO<sub>3</sub> SBF b) Liposomes in low CO<sub>3</sub> SBF +F c) Liposomes in high CO<sub>3</sub> SBF, showing the distribution of calcium, phosphate and the background silicon.

Figure 5.15 Scatter diagrams produced from X-ray maps for sample set 1 a) liposomes in low CO<sub>3</sub> SBF b) Liposomes in low CO<sub>3</sub> SBF +F c) Liposomes in high CO<sub>3</sub> SBF, showing the correlation between calcium and phosphate in the sample.

Figure 5.16 Elemental mapping diagram, liposomes in low CO<sub>3</sub> showing the distribution of selected elements over the sample.

Figure 5.17 Elemental mapping diagrams Liposomes in low CO<sub>3</sub> SBF +F showing the distribution of selected elements over the sample.

Figure 5.18 Elemental mapping diagrams Liposomes in high CO<sub>3</sub> SBF, showing the distribution of selected elements over the sample.

Figure 5.19 EDS images produced from the whole sample area for set 1 a) liposomes in low CO<sub>3</sub> SBF b) Liposomes in low CO<sub>3</sub> SBF +F c) Liposomes in high CO<sub>3</sub> SBF

- Figure 5.20 Pseudo colour images of a) liposomes produced with  $\text{CaCl}_2$  b) liposomes produced with  $\text{CaCl}_2$  plus  $\text{NaHCO}_3$  c) liposomes produced with  $\text{CaCl}_2$  plus  $\text{K}_2\text{HPO}_4$  plus  $\text{MgSO}_4$  solution.
- Figure 5.21 Scatter diagrams of a) liposomes produced with  $\text{CaCl}_2$  b) liposomes produced with  $\text{CaCl}_2$  plus  $\text{NaHCO}_3$  c) liposomes produced with  $\text{CaCl}_2$  plus  $\text{K}_2\text{HPO}_4$  plus  $\text{MgSO}_4$  solution.
- Figure 5.22 Images and EDS over the entire image of a) liposomes produced with  $\text{CaCl}_2$  b) liposomes produced with  $\text{CaCl}_2$  plus  $\text{NaHCO}_3$  c) liposomes produced with  $\text{CaCl}_2$  plus  $\text{K}_2\text{HPO}_4$  plus  $\text{MgSO}_4$  solution.
- Figure 5.23 Elemental mapping diagrams of liposomes produced with  $\text{CaCl}_2$
- Figure 5.24 Elemental mapping diagrams of liposomes produced with  $\text{CaCl}_2$  plus  $\text{NaHCO}_3$
- Figure 5.25 Elemental mapping diagrams of liposomes produced with  $\text{CaCl}_2$  plus  $\text{K}_2\text{HPO}_4$  plus  $\text{MgSO}_4$  solution.
- Figure 5.26 Mapping image with a scatter diagram showing the correlation between calcium and phosphorus, the region outlined in a black box, as the areas of high calcium and phosphorous are shown in yellow in the corresponding mapping image.
- Figure 5.27 ESEM image of the  $\text{NaCO}_3$  plus  $\text{CaCl}_2$  sample with EDS spectra obtained for the portion outlined with a red box.
- Figure 5.28 Pseudo colour image of the sample containing  $\text{CaCl}_2$ ,  $\text{KHPO}_4$  and  $\text{MgSO}_4$  with Sulphur shown in blue, phosphorous in red and calcium in green
- Figure 5.29 ESEM image with EDS spectra obtained for the portion outlined with a red box.
- Figure 5.30 ESEM image, with scatter diagram and EDS spectra of the area selected in red.
- Figure 5.31 X-ray diffraction pattern for the solution with two brushite phase present, as shown by the JCPDS reference patterns [11], shown in purple and green.

## Chapter 6

Figure 6.1 Summary of osteoblast and osteoclast cell culture studies

Figure 6.2 Bone samples in complete bone media for cell culture using explants method.

Figure 6.3 a) Cell death for Saos-2 cell line with varied liposome concentrations shows a significant increase in cell death for the 2mg/ml after day 3 b) cell death represented as a change from the control sample.

Figure 6.4 a) Cell death for Mg63 cell line with varied liposome concentrations shows a significant increase in cell death for the 2mg/ml after day 3 b) cell death represented as a change from the control sample.

Figure 6.5 a) Proliferation for Mg63 cell line with non functionalised liposome samples. Cell numbers are shown after 3,5 and 7 days of growth.

Figure 6.6 Proliferation for Mg63 cell line with functionalised liposome samples. Cell numbers are shown after 3,5 and 7 days of growth.

Figure 6.7 Proliferation for Saos-2 cell line with functionalised liposome samples. Cell numbers are shown after 3,5 and 7 days of growth.

Figure 6.8 Proliferation for Mg63 cell line with functionalised liposome samples. Cell numbers are shown after 3,5 and 7 days of growth.

Figure 6.9 ALP activity for Mg63 cell line with non functionalised liposome samples.

Figure 6.10 ALP activity for Mg63 cell line with functionalised liposome samples.

Figure 6.11 ALP activity for Saos-2 cell line with non functionalised liposome samples.

Figure 6.12 ALP activity for Saos-2 cell line with functionalised liposome samples.

Figure 6.13 Mg63 Osteocalcin production after 10 days, with different liposome samples.

Figure 6.14 Mg63 Osteoprotegerin production after 10 days, with different liposome samples.

Figure 6.15 Tibia obtained from a female Sprague Dawley rat.

Figure 6.16 Trap assay for osteoclast precursors treated with differentiation factors and liposome samples, shows all samples positive for TRAP, indicating that differentiation has occurred.

Figure 6.17 Osteoclasts, collagen release from bone in the presence of liposome samples.

## Chapter 7

Figure 7.1 Summary of cell culture work in chapter 7

Figure 7.2 a) Proliferation for U937 cell line with non functionalised liposome samples. Cell numbers are shown after 2, and 3, days of growth.

Figure 7.3 a) Proliferation for U937 cell line with functionalised liposome samples. Cell numbers are shown after 2 and 3 days of growth.

Figure 7.4 A) diagrammatic representation of DNA, RNA and protein shown [8] with B) schematic DNA RNA and Protein and involvement in various processes [7].

Figure 7.5 Phases of a PCR reaction [5]

Figure 7.6 PCR program used for IL-1, TNF, BTF, and OPG

Figure 7.7 Melting curve obtained for BTF-3 the housekeeping gene, showing the melting point at 88 °C

Figure 7.8 Melting curve obtained for TNF- $\alpha$  amplification, showing the melting point at 83°C

Figure 7.9 Melting curve obtained for OPG amplification, showing the product melting point at 87 °C

Figure 7.10 Melting curve obtained for Il-1 amplification, showing the product melting point at 86 °C

Figure 7.11 Melting curves of negative controls without template DNA. No melting points are present, as no products have formed.

Figure 7.12 Electrophoresis gels run at 60V for 90mins, showing PCR product sizes corresponding to the expected values shown in table 7.1

Figure 7.13 Proliferation of Mg63 cell line at 5 and 7 days, with U937 supernatants

Figure 7.14 ALP activity changes in the Mg63 cell line with the U937 supernatants



## List of Equations

- Equation 2.1 Conversion of DCPD to HAp  

$$\text{CaHPO}_4 + \text{Ca}_4(\text{PO}_4)_2\text{O} \rightleftharpoons \text{Ca}_5(\text{PO}_4)_3\text{OH}$$
- Equation 3.1 Bicarbonate buffering system
- $\text{CO}_2(\text{g}) + \text{H}_2\text{O} \rightleftharpoons \text{CO}_2(\text{aq}) + \text{H}_2\text{O}$  (1) dissolved  $\text{CO}_2$
- $\text{CO}_2(\text{aq}) + \text{H}_2\text{O} \rightleftharpoons \text{H}_2\text{CO}_3$  (2) carbonic acid
- $\text{H}_2\text{CO}_3 \rightleftharpoons \text{H}^+ + \text{HCO}_3^-$  (3) bicarbonate  $\text{pK}_{a1} = 6.35$  at  $25^\circ\text{C}$
- $\text{HCO}_3^- \rightleftharpoons \text{H}^+ + \text{CO}_3^{2-}$  (4) carbonate  $\text{pK}_{a2} = 10.33$  at  $25^\circ\text{C}$
- Equation 3.2 Frequency of molecular Vibrations  

$$\nu = \frac{1}{2\pi} \sqrt{\frac{k(m_1 + m_2)}{m_1 m_2}}$$
- Equation 3.3 Relationship between wavelength, incident radiation and diffraction  

$$n\lambda = 2d\sin\theta$$
- Equation 4.1 Calculation of Area of PEG dispersion  

$$A_{\text{PEG}} = \pi R_F^2$$
- Equation 4.2 Definition of Florey radius  

$$R_F = N^{3/5} a$$
- Equation 4.3 Percentage of lipid surface covered with PEG  

$$R = A_{\text{PEG}} \times M / A_{\text{lipid}}$$
- Equation 5.1 Calculation of ALP activity  

$$IU = \mu\text{mol}/(\text{L} \cdot \text{min})$$

$$= \frac{(\text{OD}_{\text{sample}_t} - \text{OD}_{\text{sample}_0}) \cdot 1000 \cdot \text{ReactionVol}}{t \cdot \epsilon \cdot l \cdot \text{samplevol}}$$

$$= \frac{(\text{OD}_{\text{sample}_t} - \text{OD}_{\text{sample}_0}) \cdot \text{ReactionVol}}{(\text{OD}_{\text{calibrator}} - \text{OD}_{\text{H}_2\text{O}}) \cdot \text{SampleVol} \cdot t}$$
- Equation 7.1. Change between gene of interest and housekeeping gene (HKG)  

$$\text{Gene 1 Ct} - \text{HKG Ct} = \Delta\text{Ct}$$
- Equation 7.2. Sample change compared to control sample  

$$\text{Sample } \Delta\text{Ct} - \text{Control } \Delta\text{Ct} = X$$
- Equation 7.3. Find fold increase, as each Cycle represents and exponential increase  

$$\text{Fold increase (or decrease)} = \text{Power}(X, 2)$$



## List of Tables

- Table 1.2 Biologically Significant Calcium phosphate compounds
- Table 2.1 Properties of the Osteoblast Phenotype
- Table 3.1 Compounds used for preparation of 1L of Kukubos SBF
- Table 3.2 Compounds used for preparation of 500ml of Kanthi's SBF
- Table 3.3 Concentrations of Ions in SBF solutions compared to blood plasma
- Table 3.4 pH readings of high carbonate SBF with storage at 37 °C and 5% CO<sub>2</sub>
- Table 3.5 Ion concentrations (mmol) in solutions used.
- Table 3.6 Different processes available for the production of Hap
- Table 3.7 Assignment of IR vibrational bands to functional groups
- Table 3.8 Calcium phosphate compounds and major identifying x-ray diffraction peaks (2 $\theta$ ) and expected relative intensities (I) values taken from JCPDS {JCPDS, 1995 #311}
- Table 5.1 Concentrations of ions compared to standard solutions
- Table 6.1 Collagenase Digest composition
- Table 6.2 Bone growth media
- Table 6.3 Summary of Cell Culture results
- Table 7.1 Primer sequences with resulting product size, and mRNA, NCBI ascension number.
- Table 7.2 Change in fold expression of OPG in U937 with liposome treatments
- Table 7.3 Change in fold expression of TNF in U937 with liposome treatments
- Table 7.4 Change in fold expression of IL-1 in U937 with liposome treatments
- Table 7.5 Change in fold expression of OPG in Mg63 with U937 supernatants